Michael Sherman, Harvard Pilgrim’s chief medical officer, during an interview with Xconomy said he’s seeing more value-based agreements for high-cost treatments such as gene therapies, cancer therapies and CAR-Ts.
Harvard Pilgrim early this year entered into a value-based deal with Spark Therapeutics for the drugmaker’s $850,000 gene therapy for vision loss, Luxturna.
Sherman says value-based deals are most needed for expensive therapies.
“I think these are the areas where we can do the most good to ensure access and also to reduce spend in areas where the drugs are less efficacious,” he said. “So gene therapy, for example, that’s an area where we as payers should be seeking to facilitate access, but doing so in a way where we’re also good stewards of the health care dollar.”